Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Biogen paid Ionis a US $ 60 million one-time upfront payment
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Anti-malaria API facility will be operational in 15-18 months
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
